JP4587199B2 - Methods for reducing the number of somatic cells in milk in dairy cows - Google Patents
Methods for reducing the number of somatic cells in milk in dairy cows Download PDFInfo
- Publication number
- JP4587199B2 JP4587199B2 JP2003415343A JP2003415343A JP4587199B2 JP 4587199 B2 JP4587199 B2 JP 4587199B2 JP 2003415343 A JP2003415343 A JP 2003415343A JP 2003415343 A JP2003415343 A JP 2003415343A JP 4587199 B2 JP4587199 B2 JP 4587199B2
- Authority
- JP
- Japan
- Prior art keywords
- milk
- vitamin
- somatic cells
- reducing
- fatty acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 235000013336 milk Nutrition 0.000 title claims description 58
- 239000008267 milk Substances 0.000 title claims description 58
- 210000004080 milk Anatomy 0.000 title claims description 58
- 210000001082 somatic cell Anatomy 0.000 title claims description 45
- 238000000034 method Methods 0.000 title claims description 22
- 241000283690 Bos taurus Species 0.000 title description 23
- 235000013365 dairy product Nutrition 0.000 title description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 56
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 26
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 26
- 229930003268 Vitamin C Natural products 0.000 claims description 26
- 235000019154 vitamin C Nutrition 0.000 claims description 26
- 239000011718 vitamin C Substances 0.000 claims description 26
- 210000004767 rumen Anatomy 0.000 claims description 19
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 18
- 229930195729 fatty acid Natural products 0.000 claims description 18
- 239000000194 fatty acid Substances 0.000 claims description 18
- 150000004665 fatty acids Chemical class 0.000 claims description 18
- 229910052751 metal Inorganic materials 0.000 claims description 16
- 239000002184 metal Substances 0.000 claims description 16
- 150000003839 salts Chemical class 0.000 claims description 16
- 229930003427 Vitamin E Natural products 0.000 claims description 13
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 13
- 239000011709 vitamin E Substances 0.000 claims description 13
- 235000019165 vitamin E Nutrition 0.000 claims description 13
- 229940046009 vitamin E Drugs 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 3
- 230000000694 effects Effects 0.000 description 18
- 208000004396 mastitis Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 7
- 241000209094 Oryza Species 0.000 description 5
- 235000007164 Oryza sativa Nutrition 0.000 description 5
- RGJHWLDSRIHFKY-FWCDDDAWSA-L calcium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-4-hydroxy-5-oxo-2h-furan-3-olate;dihydrate Chemical compound O.O.[Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] RGJHWLDSRIHFKY-FWCDDDAWSA-L 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 235000009566 rice Nutrition 0.000 description 5
- BLORRZQTHNGFTI-ZZMNMWMASA-L calcium-L-ascorbate Chemical compound [Ca+2].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] BLORRZQTHNGFTI-ZZMNMWMASA-L 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 239000002967 calcium-L-ascorbate Substances 0.000 description 3
- 235000005937 calcium-L-ascorbate Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000000392 somatic effect Effects 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 239000002211 L-ascorbic acid Substances 0.000 description 2
- 235000000069 L-ascorbic acid Nutrition 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- DYUQIXOTDWLZOA-RXSVEWSESA-N calcium;(2r)-2-[(1s)-1,2-dihydroxyethyl]-3,4-dihydroxy-2h-furan-5-one Chemical compound [Ca].OC[C@H](O)[C@H]1OC(=O)C(O)=C1O DYUQIXOTDWLZOA-RXSVEWSESA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 240000004670 Glycyrrhiza echinata Species 0.000 description 1
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- BKUUXNDFQMLXLN-YCWPWOODSA-L [Na+].[Ca+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O Chemical compound [Na+].[Ca+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O BKUUXNDFQMLXLN-YCWPWOODSA-L 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 235000010376 calcium ascorbate Nutrition 0.000 description 1
- 239000011692 calcium ascorbate Substances 0.000 description 1
- 229940047036 calcium ascorbate Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940010454 licorice Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000010330 ougon Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 238000005453 pelletization Methods 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- -1 phosphate ester Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 235000011649 selenium Nutrition 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Feed For Specific Animals (AREA)
- Fodder In General (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、乳中体細胞数を減少させる方法に関し、さらに詳しくはルーメンバイパスするビタミンCを投与することによる乳中体細胞数を減少させる方法およびそれに用いる製剤に関する。 The present invention relates to a method for reducing the number of somatic cells in milk, and more particularly to a method for reducing the number of somatic cells in milk by administering vitamin C that bypasses rumen, and a preparation used therefor.
酪農家による牛乳の生産段階では、乳蛋白、乳脂肪、無脂固形分、乳中体細胞数といった乳質に関する指標について、それぞれ基準値が設定されている。これらの基準を満たさない場合、乳価へのペナルティーを受け、場合によっては牛乳が出荷停止になることから、酪農家にとってこれらの基準を満たすことは非常に重要となっている。しかしながらこのような指標のうち、特に乳中体細胞数のコントロールは難しく、多くの酪農家において基準値を超えることはめずらしくない。 At the milk production stage by dairymen, standard values are set for indices relating to milk quality such as milk protein, milk fat, non-fat solids, and the number of somatic cells in milk. If these criteria are not met, it will be very important for dairymen to be penalized for milk price and in some cases milk will be suspended. However, among these indicators, it is difficult to control the number of somatic cells in milk, and it is not uncommon for many dairymen to exceed the standard value.
現在、乳中の体細胞数が増加する原因の大部分は乳房炎に罹患することによるものと考えられている。乳中体細胞数という指標は主に乳中の白血球数を示しており、乳中体細胞数の増加は乳房中の乳腺への細菌感染、すなわち乳房炎の罹患を意味する。乳房炎は重度の場合、牛を死に至らしめることがあり、また軽度(いわゆる潜在性)であっても乳量の減少や乳質の低下に至るなど、酪農家にとって多大な経済的損失をもたらす厄介な疾病である。このように、乳中体細胞数と乳房炎とは密接に関係しており、乳中体細胞数を減らすことは同時に乳房炎の改善につながる。 Currently, most of the causes of increased somatic cell count in milk are thought to be due to mastitis. The index of somatic milk cell count mainly indicates the white blood cell count in milk, and an increase in the somatic milk cell count means bacterial infection of the mammary gland in the breast, that is, mastitis. Mastitis, if severe, can cause cattle to die and, even if mild (so-called potential), can lead to significant economic losses for dairymen, such as reduced milk yield and reduced quality. It is a serious disease. Thus, the number of somatic cells in milk and mastitis are closely related, and reducing the number of somatic cells in milk leads to improvement of mastitis at the same time.
現在、乳房炎を予防するために乾乳期や搾乳の前後に乳頭を消毒剤に浸漬させることが行われており、そのための製剤も提案されている(特許文献1参照)。また乳房炎に罹患した際の治療方法として、獣医師により抗生物質などの投与が行われているが、治療代がかかることや治療後に一定期間牛乳の出荷が制限されるなど酪農家にとって経済的損失は大きい。そして抗生物質の使用は薬剤耐性菌の発生につながるなど安全性の面で問題が残る。 At present, in order to prevent mastitis, nipples are immersed in a disinfectant before and after milking and milking, and a preparation for that purpose has also been proposed (see Patent Document 1). In addition, antibiotics are administered by veterinarians as a treatment method when suffering from mastitis, but it is economical for dairymen because it costs a treatment fee and milk shipment is restricted for a certain period after treatment. The loss is great. And the use of antibiotics remains problematic in terms of safety, such as leading to the development of drug-resistant bacteria.
そのような問題を回避するため、飼料の配合成分を工夫して乳中体細胞数を減少させること(すなわち乳房炎の予防または改善)も試みられており、カンゾウ、オウレン、オウゴン、コウボク等の生薬を投与する方法(特許文献2参照)、クエン酸、コハク酸、フマル酸、リンゴ酸等の有機酸を投与する方法(特許文献3参照)、ルーメンバイパスするビタミンAとメチオニンを投与する方法(特許文献4参照)等が提案されている。その他、ビタミンA、ビタミンE、βカロチン、セレンなどの抗酸化性飼料添加剤が、比較的安価でかつ酪農家自身が簡単に取り扱える点から一般的に広く用いられている。しかし、これらの方法は、効果的に乳中体細胞数を減らすことはできず、未だ乳房炎の発生数が減少に至っていないことから、これらの方法に変わる有効な対策が求められている。 In order to avoid such problems, attempts have been made to reduce the number of somatic cells in the milk by devising the composition of the feed (ie, prevention or improvement of mastitis), such as licorice, auren, ougon, koboku, etc. A method of administering a crude drug (see Patent Document 2), a method of administering an organic acid such as citric acid, succinic acid, fumaric acid, malic acid (see Patent Document 3), a method of administering vitamin A and methionine bypassing rumen ( Patent Document 4) has been proposed. In addition, antioxidant feed additives such as vitamin A, vitamin E, β-carotene, and selenium are generally widely used because they are relatively inexpensive and can be easily handled by dairymen themselves. However, these methods cannot effectively reduce the number of somatic cells in the milk, and the number of mastitis has not yet been reduced. Therefore, effective measures to replace these methods are required.
一方、ビタミンCは、肉牛に投与すると肉質を改善する効果があることが知られている(特許文献5、非特許文献1および非特許文献2参照)。また、ストレスや風邪などの予防のため、油脂被覆ビタミンCを黒毛和牛に投与した例が知られている(特許文献6参照)。しかしながら、ビタミンCを乳牛に投与することにより、乳中体細胞数が著しく減少することは知られていない。 On the other hand, vitamin C is known to have an effect of improving meat quality when administered to beef cattle (see Patent Document 5, Non-Patent Document 1 and Non-Patent Document 2). In addition, there is known an example in which fat and oil-coated vitamin C is administered to Japanese black cattle for prevention of stress and cold (see Patent Document 6). However, it is not known that administration of vitamin C to dairy cows significantly reduces the number of somatic cells in milk.
本発明は、安全でかつ効果的に乳中体細胞数を減少させる方法およびそれに用いる製剤を提供するものである。 The present invention provides a method for reducing the number of somatic cells in milk safely and effectively, and a preparation used therefor.
本発明者らは、上記課題を解決するため、乳中体細胞数が高い乳牛にビタミンCを経口投与したところ、乳中体細胞数が著しく減少し、乳房炎が改善されることを見出し、本発明を完成した。すなわち、本発明は、以下の(1)〜(6)に関する。 In order to solve the above-mentioned problems, the present inventors found that when vitamin C was orally administered to a dairy cow having a high number of somatic cells in milk, the number of somatic cells in milk was significantly reduced and mastitis was improved. The present invention has been completed. That is, the present invention relates to the following (1) to (6).
(1)脂肪酸金属塩で被膜されたルーメンバイパスするビタミンCを乳牛に経口投与することを特徴とする乳中体細胞数を減少させる方法。
(2)脂肪酸金属塩で被膜されたルーメンバイパスするビタミンCおよび脂肪酸金属塩で被膜されたルーメンバイパスするビタミンEを乳牛に経口投与することを特徴とする乳中体細胞数を減少させる方法。
(3)ビタミンCとして日量1頭当たり0.3〜100g経口投与することを特徴とする(1)または(2)記載の方法。
(1) A method for reducing the number of somatic cells in milk, which comprises orally administering to a cow a rumen bypass vitamin C coated with a fatty acid metal salt .
(2) A method for reducing the number of somatic cells in milk, which comprises orally administering to a cow a rumen bypass vitamin C coated with a fatty acid metal salt and a lumen bypass vitamin E coated with a fatty acid metal salt .
(3) The method according to (1) or (2), wherein 0.3 to 100 g per day as vitamin C is orally administered.
(4)ビタミンEとして日量1頭当たり0.6〜30g経口投与することを特徴とする(2)記載の方法。
(5)脂肪酸金属塩で被膜されたルーメンバイパスするビタミンCを含有してなる乳中体細胞数を減少させるための製剤。
(6)脂肪酸金属塩で被膜されたルーメンバイパスするビタミンCおよび脂肪酸金属塩で被膜されたルーメンバイパスするビタミンEを含有してなる乳中体細胞数を減少させるための製剤。
(4) The method according to (2), wherein 0.6-30 g per day as vitamin E is orally administered.
(5) A preparation for reducing the number of somatic cells in milk, comprising vitamin C bypassing a lumen coated with a fatty acid metal salt .
(6) preparation for reducing milk somatic cell count which comprises vitamin E for rumen bypass is coated with vitamin C and fatty acid metal salt rumen bypass which is coated with a fatty acid metal salt.
本明細書で用いる「ルーメンバイパスするビタミンC」という用語は、牛の第1胃(ルーメン)の微生物による分解から保護され、第4胃以降で消化吸収されビタミンCとしての活性を示すようにしたビタミンC製剤を意味する。ルーメンバイパスするための方法は、公知の手法であればどのようなものでも使用することができるが、好ましい例として、特公昭56−1057号公報や特公昭59−10780号公報に記載された方法により製造された脂肪酸金属塩等で被膜されたものを挙げることができる。これは、簡単に製造することができる上、バイパスの効果が高く、さらにペレット化あるいは顆粒化等の造粒加工を施すことにより、より一層バイパスの効果を高めることができるものである。その際に脂肪酸金属塩として使用する脂肪酸は特に限定はされないが、嗜好性を高めるために大豆や米などの植物由来の脂肪酸を用いることが好ましい。 As used herein, the term “lumen-bypassing vitamin C” is protected from microbial degradation of the rumen of the cow, digested and absorbed in the 4th and subsequent stomachs, and exhibits activity as vitamin C. It means vitamin C preparation. Any method for bypassing the lumen can be used as long as it is a known method, but preferred examples include the methods described in Japanese Patent Publication Nos. 56-1057 and 59-10780. And those coated with a fatty acid metal salt or the like produced by the above method. This can be easily manufactured, has a high bypass effect, and can further enhance the bypass effect by performing granulation such as pelletization or granulation. In this case, the fatty acid used as the fatty acid metal salt is not particularly limited, but it is preferable to use a plant-derived fatty acid such as soybean or rice in order to enhance palatability.
またルーメンバイパスされるビタミンCは、遊離のL−アスコルビン酸であっても金属塩であってもよく、またリン酸エステルの金属塩であってもよい。好ましいものとして、L−アスコルビン酸、L−アスコルビン酸カルシウム、L−アスコルビン酸−2−リン酸エステルナトリウムカルシウム、L−アスコルビン酸−2−リン酸エステルマグネシウム等を挙げることができるが、なかでもL−アスコルビン酸カルシウムが最も好ましい。 Vitamin C bypassed by rumen may be free L-ascorbic acid or a metal salt, or may be a metal salt of a phosphate ester. Preferred examples include L-ascorbic acid, L-ascorbic acid calcium, L-ascorbic acid-2-phosphate sodium calcium, L-ascorbic acid-2-phosphate magnesium, etc. Among them, L -Most preferred is calcium ascorbate.
本明細書で用いる「乳中体細胞数を減少させる」という用語は、単に「乳中体細胞数が増加して乳価のペナルティーや出荷停止を受けてしまった乳牛の乳中体細胞数を減少させること」だけでなく、「乳価のペナルティーや出荷停止を受けていない乳牛の乳中体細胞数を出荷できるレベルに維持させること」をも意味する。 As used herein, the term “decrease milk somatic cell count” simply means “decrease milk somatic cell count in dairy cows that have been subject to milk price penalties or shipment suspension due to increased milk somatic cell count. It means "to maintain the milk somatic cell count of dairy cows that have not received a milk price penalty or shipment suspension at a level that can be shipped".
乳牛へのルーメンバイパスするビタミンCの投与量は、日量1頭あたりビタミンCとして0.3〜100gがよく、効果の観点から5〜50g、経済性を考え合わせると少なくとも2g与えることが好ましい。乳中体細胞数が著しく高い場合や即座に低下させる場合には10〜100gがよく、この効果を持続させる場合または正常な体細胞数を維持し高くなることを予防する場合には0.3〜30gが好ましい。0.3g未満の場合、第1胃での分解によるロスや牛体内での様々な作用によるロスが大きいことなどから、本来の乳中体細胞数改善に十分な効果が期待できない。1日の投与で十分な効果が得られる場合が多いが、休止期間を挟んで複数回の投与、あるいは連続投与でさらに安定した効果が期待できる。 The dose of vitamin C that bypasses the rumen to dairy cows is preferably 0.3 to 100 g as vitamin C per head, and it is preferably 5 to 50 g from the viewpoint of the effect, and at least 2 g is preferable considering economy. When the number of somatic cells in milk is extremely high or immediately decreases, 10 to 100 g is good. When this effect is maintained or when normal somatic cell number is maintained and increased, it is 0.3. -30 g is preferred. When the amount is less than 0.3 g, a loss due to decomposition in the rumen and a loss due to various actions in the bovine body are large, and thus a sufficient effect for improving the number of somatic cells in milk cannot be expected. In many cases, a sufficient effect can be obtained by daily administration, but a more stable effect can be expected by multiple administrations or continuous administrations over a rest period.
また乳中体細胞数を減少させるためには、ルーメンバイパスするビタミンCの単独投与でもよいが、ルーメンバイパスするビタミンEとの併用によりさらに優れた効果が期待できる。乳牛へのルーメンバイパスするビタミンEの投与量は、日量1頭あたりビタミンEとして0.6〜30gがよく、効果の観点から好ましくは5〜30g、経済性の観点から少なくとも2g与えることが好ましい。 Moreover, in order to reduce the number of somatic cells in milk, single administration of rumen bypass vitamin C may be performed, but a more excellent effect can be expected by combined use with rumen bypass vitamin E. The dose of vitamin E that bypasses the rumen to dairy cows should be 0.6-30 g per day as vitamin E, preferably 5-30 g from the viewpoint of effect, and preferably at least 2 g from the viewpoint of economy. .
以下、具体例を挙げて、さらに本発明を説明する。 Hereinafter, the present invention will be further described with specific examples.
実施例1 ルーメンバイパス製剤の製造1
ビタミンCカルシウム塩(L−アスコルビン酸カルシウム)600gを、加熱融解した米油300gおよび米油脂肪酸カルシウム100gに攪拌しながら均一に混合した後、ノズルから滴下させ、粒状(粒径1〜2mm)のルーメンバイパス製剤1000g(組成物1)を得た。
Example 1 Production of Lumen Bypass Formulation 1
600 g of vitamin C calcium salt (calcium L-ascorbate) was mixed uniformly with stirring in 300 g of heated and melted rice oil and 100 g of rice oil fatty acid calcium, and then dripped from a nozzle to form a granular (particle size of 1 to 2 mm) 1000 g of rumen bypass preparation (Composition 1) was obtained.
実施例2 ルーメンバイパス製剤の製造2
ビタミンCカルシウム塩(L−アスコルビン酸カルシウム)400g、ビタミンE粉末200g、米油300gおよび米油由来脂肪酸カルシウム100gを攪拌しながら均一に混合した後、実施例1と同様の方法で粒状(粒径1〜2mm)のルーメンバイパス製剤1000g(組成物2)を得た。
Example 2 Production 2 of Lumen Bypass Formulation 2
Vitamin C calcium salt (L-ascorbic acid calcium) 400 g, vitamin E powder 200 g, rice oil 300 g and rice oil-derived fatty acid calcium 100 g were mixed uniformly with stirring, and then granulated (particle size in the same manner as in Example 1). 1 to 2 mm) of a lumen bypass preparation 1000 g (Composition 2) was obtained.
実施例3
乳中体細胞数200万個/ml以上のホルスタイン種雌牛9頭を選び、試験開始当日(1回目投与)および開始3日目(2回目投与)に日量1頭当たり組成物1を50gを与えるB−VC区、ビタミンCカルシウム塩(L−アスコルビン酸カルシウム)を30g与えるVC区、組成物2を75g与えるB−VCE区に対して、各3頭ずつに分けて試験を行った。各区とも試験開始前日、1回目投与翌日、2回目投与翌日、2回目投与日から数えて7日後および20日後の乳中体細胞数を測定し、表1にまとめて示した。なお、()内に乳中体細胞数のレベルを記号化して示した。
+++:200万個/ml以上、++ :100万個/ml以上200万個/ml未満、+ :30万個/ml以上100万個/ml未満、−:30万個/ml以下
レベル−は、基準値以下であり、乳価へのペナルティーは課せられない。
Example 3
Nine Holstein cows with a milk somatic cell count of 2 million cells / ml or more were selected, and 50 g of composition 1 per head was given on the day of the test (first administration) and the third day (second administration). The test was carried out separately for each of the 3 groups of B-VC group to be fed, VC group to which 30 g of vitamin C calcium salt (calcium L-ascorbate) was fed, and B-VCE group to which 75 g of composition 2 was fed. In each group, the number of somatic cells in the milk 7 days and 20 days after the first day of the test, the day after the first administration, the day after the second administration, and the day after the second administration were measured and summarized in Table 1. In addition, the level of the number of somatic cells in milk is symbolized and shown in parentheses.
++: 2 million pieces / ml or more, ++: 1 million pieces / ml or more and less than 2 million pieces / ml, +: 300,000 pieces / ml or more and less than 1 million pieces / ml, −: 300,000 pieces / ml or less
The level is below the reference value and no penalty is imposed on the milk price.
この結果、投与前には非常に高い乳中体細胞数であったにもかかわらず、B−VC区およびB−VCE区では、1回目の投与で著しく減少し、2回目の投与ではどの牛もペナルティーを回避できる基準体細胞数30万個/ml以下になった。B−VCE区では、B−VCと同じかまたはそれ以上の有効な結果であり、ビタミンCの効果はビタミンEによって相乗的に高められた。また、投与中止後の20日間はどの牛もほとんどが30万個以下であり、効果の持続性が見られた。VC区では、投与により減少傾向であるものの、2回投与後も他区に比べて高い結果であった。 As a result, in the B-VC and B-VCE groups, although the number of somatic cells in the milk was very high before administration, the number of cows decreased significantly in the first administration and in which cow in the second administration. The number of standard somatic cells that can avoid the penalty was 300,000 cells / ml or less. In the B-VCE section, the results were as effective as or better than B-VC, and the effect of vitamin C was synergistically enhanced by vitamin E. In addition, most of the cows were less than 300,000 for 20 days after the cessation of administration, and the effect was sustained. In the VC group, although it was on a decreasing trend due to administration, the results were higher after the second administration than in the other groups.
実施例4
乳中体細胞数 200万個/ml以上のホルスタイン種雌牛9頭を選び、組成物1を日量1頭あたり50gを与える1回投与区、2日連続で与える2回投与区、5日連続で与える5回投与区とし、各3頭ずつに分けて試験を行った。各区とも試験開始前日、各投与日翌日、最後の投与日から数えて7日後および20日後の乳中体細胞数を測定し、表2にまとめて示した。なお、()内に実施例3と同様に乳中体細胞数のレベルを記号化して示した。
Example 4
Choose 9 Holstein cows with 2 million somatic milk / ml or more in milk, 1 dose group giving 50 g of daily dose per composition, 2 dose groups given 2 consecutive days, 5 days consecutive The test group was divided into 3 groups, each of which was divided into 5 dose groups. In each group, the number of somatic cells in the milk was measured on the day before the start of the test, the day after each administration day, and 7 days and 20 days after the last administration day. In addition, the level of the number of somatic cells in the milk is symbolized in parentheses in the same manner as in Example 3.
各区ともに投与前は、どの牛も非常に高い乳中体細胞数であったが、組成物1の投与回数を増やすごとに著しく減少し、また投与中止後の効果の持続性も有意に高まった。特に5回投与区では、投与中止後の20日間はどの牛もほとんど30万個以下を維持しており、効果の持続性は最も高かった。 Before treatment, each cow had a very high number of somatic cells in milk, but it decreased significantly with each increase in the number of doses of Composition 1, and the sustainability of the effect after discontinuation was significantly increased. . In particular, in the 5th administration group, almost no cattle maintained 300,000 or less for 20 days after the discontinuation of administration, and the sustainability of the effect was the highest.
実施例5
乳中体細胞数が100万/ml以上のホルスタイン種雌牛15頭を選び、気温が高い7月および8月の2ヶ月間にわたり、1日1頭当たり組成物1を20g与えるB−VC区、ビタミンCカルシウム塩(L−アスコルビン酸カルシウム)を12g与えるVC区、および与えない対照区に対して、各5頭ずつに分けて試験を行った。各区とも試験開始前日、1ヵ月後、2ヵ月後、3ヵ月後の乳中体細胞数を測定し、各5頭の平均値を表3にまとめて示した。なお、()内に乳中体細胞数のレベルを記号化して示した。
+++:100万個/ml以上、++ :70万個/ml以上100万個/ml未満、+ :30万個/ml以上70万個/ml未満、−:30万個/ml以下
レベル−は、基準値以下であり、乳価へのペナルティーは課せられない。
Example 5
B-VC section that selects 15 Holstein cows with a somatic cell count in the milk of 1 million / ml or more and gives 20 g of composition 1 per head for two months in July and August when the temperature is high. The test was conducted separately for each of the 5 groups of the VC group to which 12 g of vitamin C calcium salt (calcium L-ascorbate) was given and the control group to which 12 g of vitamin C calcium salt was not given. In each group, the number of somatic cells in milk was measured on the day before the start of the test, 1 month later, 2 months later, and 3 months later, and the average value of each 5 animals is shown in Table 3. In addition, the level of the number of somatic cells in milk is symbolized and shown in parentheses.
++: 1 million pieces / ml or more, ++: 700,000 pieces / ml or more and less than 1 million pieces / ml, +: 300,000 pieces / ml or more and less than 700,000 pieces / ml, −: 300,000 pieces / ml or less
The level is below the reference value and no penalty is imposed on the milk price.
この結果、B−VC区においては、組成物1の1ヶ月間の投与により、ペナルティーを回避できる基準体細胞数にまで減少し、さらに投与を中止して1ヶ月後でも乳中体細胞数の基準値よりもはるかに低い値を維持する非常に良好な結果であった。VC区においても、乳中体細胞数は減少傾向を示し、ある程度の効果は得られたが、ビタミンCを与えない対照区は、改善傾向を示さず、むしろ悪化した。 As a result, in the B-VC section, administration of Composition 1 for one month reduces the number of somatic cells to avoid penalties, and further discontinues administration, and the number of somatic cells in milk is one month later. It was a very good result maintaining a value much lower than the reference value. Even in the VC group, the number of somatic cells in milk showed a decreasing trend, and a certain degree of effect was obtained. However, the control group not given vitamin C did not show an improvement trend but rather deteriorated.
以上の結果より、乳牛へルーメンバイパスするビタミンCを経口投与することにより乳中体細胞数は減少し、さらにビタミンCとビタミンEを併用することにより高い効果が得られることが示された。このことは、本発明が乳価ペナルティーの回避のみならず、乳房炎そのものの改善にも非常に有効であることを示しており、酪農産業に多大な経済的効果をもたらす発明と言える。
From the above results, it was shown that the number of somatic cells in milk decreased by oral administration of vitamin C that bypasses rumen to dairy cows, and that a high effect was obtained by using vitamin C and vitamin E together. This indicates that the present invention is very effective not only for avoiding a milk price penalty but also for improving mastitis itself, and can be said to be an invention that has a great economic effect on the dairy industry.
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003415343A JP4587199B2 (en) | 2003-12-12 | 2003-12-12 | Methods for reducing the number of somatic cells in milk in dairy cows |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003415343A JP4587199B2 (en) | 2003-12-12 | 2003-12-12 | Methods for reducing the number of somatic cells in milk in dairy cows |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005170889A JP2005170889A (en) | 2005-06-30 |
JP4587199B2 true JP4587199B2 (en) | 2010-11-24 |
Family
ID=34734870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003415343A Expired - Lifetime JP4587199B2 (en) | 2003-12-12 | 2003-12-12 | Methods for reducing the number of somatic cells in milk in dairy cows |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4587199B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000281575A (en) * | 1999-03-25 | 2000-10-10 | Kyokuto Internatl Corp | Reinforcement of immune activity of domestic animal by oral feeding of oil and fat-coated vitamin c, and protection of stress and prevention of wastage |
-
2003
- 2003-12-12 JP JP2003415343A patent/JP4587199B2/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000281575A (en) * | 1999-03-25 | 2000-10-10 | Kyokuto Internatl Corp | Reinforcement of immune activity of domestic animal by oral feeding of oil and fat-coated vitamin c, and protection of stress and prevention of wastage |
Also Published As
Publication number | Publication date |
---|---|
JP2005170889A (en) | 2005-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3054784B1 (en) | Composition and fodder comprising medium chain fatty acids | |
RU2352139C2 (en) | Method of increasing bone strength of pigs, respective composition, its use, feed stuff and premix for pigs | |
NL1021963C1 (en) | Antimicrobial composition for animals. | |
JP2007501632A (en) | Dietary supplements and methods of treating and preventing gastrointestinal ulcers in horses and other animals | |
JP4587199B2 (en) | Methods for reducing the number of somatic cells in milk in dairy cows | |
US20140228329A1 (en) | Use of 25-hydroxy vitamin d3 to promote phosphorous utilisation in ruminants | |
KR20010074799A (en) | Method for Increasing Milk Production in Lactating Dairy Cattle | |
KR20050087916A (en) | Feed additives for decreasimg somatic cell count of lactating dairy cow and production method of milk from the cow | |
JP4180795B2 (en) | How to prevent and treat mastitis | |
JP7066888B2 (en) | Method of increasing milk yield and milk fat content of ruminant livestock | |
JP2002507123A (en) | Method for improving the effectiveness of probiotics, preparation of nutritional additives and animal feed containing same | |
JP2000281575A (en) | Reinforcement of immune activity of domestic animal by oral feeding of oil and fat-coated vitamin c, and protection of stress and prevention of wastage | |
JP2005531318A (en) | Vitamin-containing systems to stabilize animal immune responses | |
JP2011182748A (en) | Feed for livestock or poultry | |
JPH07309750A (en) | Central nervous stabilizer for ruminant | |
JP3878011B2 (en) | Livestock mastitis preventive | |
RU2081634C1 (en) | Curative-prophylaxis agent | |
JP2784090B2 (en) | Feeding feed for meat and livestock | |
JP5112573B1 (en) | Mastitis prevention and treatment composition | |
JPS62138148A (en) | Feed additive for aquatic animal | |
JP2002209528A (en) | Method for improving meat quality of beef cattle | |
JP2547400B2 (en) | Veterinary drug | |
JP2004292349A (en) | Ammonia absorption inhibition composition containing aldonic acid | |
JP5899098B2 (en) | Blue odor control agent for livestock milk | |
RU2158517C1 (en) | Physiologically active agent for farm animals and poultry, method of preparation thereof, feed additive, and method of feeding animals and poultry |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051116 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090714 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20091104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20091224 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100309 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100510 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20100610 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100901 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100901 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 4587199 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130917 Year of fee payment: 3 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |